Boehringer Ingelheim Vetmedica Gmbh

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingleheim Vetmedica, Inc.

Juergen Daemmgen

Olaf Joens

Rainer Kleemann

Eric Martin Vaughn

Christian Troetschel

Andrea Vollmar

Brian Guth

Paulino Carlos Gonzalez-Hernandez

Randolph Seidler

Olaf JÖNS

Paulino Carlos Gonzalez-Hemandez

A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.

PDE III inhibitors for treatment of asymptomatic heart failure

A phosphodiesterase type III (PDE III) inhibitor or Ca-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Use of pimobendan for the reduction of heart size in mammals suffering from heart failure

Phosphodiesterase type III (PDE III) inhibitor or a 'Ca-sensitizing agent' or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.

The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.

H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.

Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure

The present invention relates to a method of reducing the transmission of a pathogen from an animal of a first species to an animal of a second species. Specifically, reduction of transmission is accomplished through the administration of antigen of the pathogen such that administration results in the reduction or absence of the reproduction of the pathogen in the animal to which the antigen was administered.

Use of vaccines for the treatment/prevention of the transmission of pathogens

The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca-sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

[object Object]

The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.

Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

The present invention relates to the new use of bradycardiac substances such as a Cachannel blocker, beta-receptor blocker or ichannel blocker, the ichannel blockers being preferred, optionally in combination with a cardioactive substance for inducing the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.

Growing community of inventors

Ochsenhausen, Germany

Juergen Daemmgen